Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Phase 4

Completed

Conditions: Medication Non Adherence
Medication Adherence
Bipolar Disorder

Interventions: Drug: Abilify Maintena
Behavioral: Customized Adherence Enhancement (CAE)

First Posted Date: 2018-01-24

Last Posted Date: 2022-02-17

Lead Sponsor: Martha Sajatovic

Target Recruit Count: 30

Registration Number: NCT03408873

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

Phase 4

Completed

Conditions: Long-Acting Injection
LAI
Aripiprazole
Schizophrenia
Antipsychotics

Interventions: Drug: Abilify maintena

First Posted Date: 2017-12-18

Last Posted Date: 2021-12-17

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 201

Registration Number: NCT03376763

Locations: 🇰🇷
Cha Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Eulji University Hospital, Daejeon, Korea, Republic of
🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of

and more 24 locations

Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

Phase 1

Completed

Conditions: Healthy Male Adults

Interventions: Drug: ASC-01
Drug: Aripiprazole and sertraline

First Posted Date: 2017-11-17

Last Posted Date: 2021-05-03

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 74

Registration Number: NCT03342963

Locations: 🇯🇵
Clinic of Kyusyu Region, Fukuoka, Japan

Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study

Phase 4

Completed

Conditions: Acute Schizophrenia Episode

Interventions: Drug: Aripiprazole

First Posted Date: 2017-09-20

Last Posted Date: 2021-02-05

Lead Sponsor: Peking University

Target Recruit Count: 770

Registration Number: NCT03289026

Locations: 🇨🇳
Beijing Anding Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Shandong Mental Health Center, Jinan, Shandong, China

and more 9 locations